NuPathe Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. The Company’s lead product, Zecuity (sumatriptan iontophoretic transdermal system), was approved by the Food and Drug Administration (FDA) in January 2013 for the acute treatment of migraine with or without aura in adults. Zecuity is a single-use, battery-powered patch applied to the upper arm or thigh during a migraine. Following application and with a press of a button, Zecuity initiates transdermal delivery (through the skin) of medication, bypassing the gastrointestinal tract.